U.S. Markets open in 8 hrs 34 mins

Spark Unlikely To Get A Better Bid — But These Stocks Could Be In Play

ALLISON GATLIN
Spark Unlikely To Get A Better Bid — But These Stocks Could Be In Play

Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.